Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

In this trial, the addition of pertuzumab to trastuzumab and chemotherapy in early-stage HER2-positive breast cancer improved the rate of invasive-disease–free survival at the cost of an increase in diarrhea incidence.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2017-07, Vol.377 (2), p.122-131
Hauptverfasser:	von Minckwitz, Gunter, Procter, Marion, de Azambuja, Evandro, Zardavas, Dimitrios, Benyunes, Mark, Viale, Giuseppe, Suter, Thomas, Arahmani, Amal, Rouchet, Nathalie, Clark, Emma, Knott, Adam, Lang, Istvan, Levy, Christelle, Yardley, Denise A, Bines, Jose, Gelber, Richard D, Piccart, Martine, Baselga, Jose
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants Adult Aged Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - surgery Cancer therapies Chemotherapy Chemotherapy, Adjuvant Death Diarrhea - chemically induced Disease-Free Survival Double-Blind Method Epidermal growth factor ErbB-2 protein Female Heart Failure - chemically induced Humans Immunotherapy Invasiveness Metastases Middle Aged Monoclonal antibodies Neutropenia Oncology Patients Pharmaceuticals Receptor, ErbB-2 - analysis Survival Survival Rate Targeted cancer therapy Trastuzumab Trastuzumab - adverse effects Trastuzumab - therapeutic use Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In this trial, the addition of pertuzumab to trastuzumab and chemotherapy in early-stage HER2-positive breast cancer improved the rate of invasive-disease–free survival at the cost of an increase in diarrhea incidence.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1703643